1. Bosentan and oral anticoagulants in HIV patients: what we can learn of cases reported so far
- Author
-
Juan Enrique Martínez de la Plata, Olivia Urquízar-Rodríguez, María Angustias Molina-Arrebola, Jose Antonio Morales-Molina, [Morales-Molina, JA, Martinez-de la Plata, JE, and Urquízar-Rodríguez, O] Pharmacy Department, Hospital de Poniente, El Ejido, Almeria, Spain [Molina-Arrebola, MA] Haematology Department, Hospital de Poniente, El Ejido, Almeria, Spain
- Subjects
Pediatrics ,medicine.medical_specialty ,Interacciones de Drogas ,MEDLINE ,Human immunodeficiency virus (HIV) ,Diseases::Virus Diseases::Sexually Transmitted Diseases::Sexually Transmitted Diseases, Viral::HIV Infections [Medical Subject Headings] ,Case Report ,HIV patients ,medicine.disease_cause ,Chemicals and Drugs::Heterocyclic Compounds::Heterocyclic Compounds, 2-Ring::Benzopyrans::Coumarins::4-Hydroxycoumarins::Acenocoumarol [Medical Subject Headings] ,Phenomena and Processes::Physiological Phenomena::Pharmacological Phenomena::Pharmacological Processes::Drug Interactions [Medical Subject Headings] ,Medicine ,Drug Interactions ,Severe complication ,Acenocoumarol ,bosentan ,lcsh:RC633-647.5 ,acenocoumarol ,business.industry ,Warfarin ,VIH ,Bosentan ,lcsh:Diseases of the blood and blood-forming organs ,drug interactions ,Hematology ,Warfarina ,Acenocumarol ,respiratory tract diseases ,warfarin ,Named Groups::Persons::Patients [Medical Subject Headings] ,Hiv patients ,Chemicals and Drugs::Heterocyclic Compounds::Heterocyclic Compounds, 2-Ring::Benzopyrans::Coumarins::4-Hydroxycoumarins::Warfarin [Medical Subject Headings] ,Hipertensión Pulmonar ,business ,acenocoumarol, bosentan, drug interactions, warfarin, HIV patients ,medicine.drug ,HIV Patients - Abstract
Journal Article; Pulmonary arterial hypertension is an infrequent but nevertheless serious life-threatening severe complication of HIV infection. It can be treated with bosentan and oral anticoagulants. Bosentan could induce the acenocoumarol metabolism and it increases the INR values. Until now, no study of interaction between bosentan and oral anticoagulants in HIV patients has reported. So we present a case of this interaction between these drugs and we reviewed MEDLINE to identify all the papers published so far. In our case, several weeks after increasing dose of bosentan acenocoumarol dose had to be progressively increased to 70 mg/week (+33%) without obtaining an adequate INR level (2.0-3.0). Forty-nine days later, we achieved a therapeutic INR with 90 mg/week of warfarin. The use of bosentan and oral anticoagulants together in these patients require a closer monitoring during first weeks of treatment, after increasing the bosentan dose and even during longer periods of time. Yes
- Published
- 2011